The benzyl alcohol preservative inhibits bacterial growth in reconstituted solutions, allowing researchers to access the same vial multiple times over an extended period without sterility risk the key practical advantage that makes it the preferred reconstitution solvent for peptide research across EU and European laboratories
A planned Phase I safety trial of 42 healthy volunteers receiving oral BPC-157 was conducted in 2015, but results were never formally published following cancellation of planned submission in 2016
The only remaining question in this story is why
Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD et al
this process involved denaturation, enzyme reaction, and thermal cycling to produce stable complementary DNA for subsequent analysis
We found the sweet spot to be 750 milligrams